AIMD - Ainos, Inc. Stock Price, Fair Value and News

1.06USD+0.02 (+1.92%)Delayed as of 17 May 2024, 10:04 am ET

Market Summary

USD1.06+0.02

Delayedas of 17 May 2024, 10:04 am

1.92%

AIMD Stock Price

View Fullscreen

AIMD RSI Chart

AIMD Valuation

Market Cap

6.5M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

69.77

EV/EBITDA

-0.58

Price/Free Cashflow

-1.35

AIMD Price/Sales (Trailing)

AIMD Profitability

Operating Margin

-222.12%

EBT Margin

-15547.13%

Return on Equity

-64.22%

Return on Assets

-48.95%

Free Cashflow Yield

-74.28%

AIMD Fundamentals

AIMD Revenue

Revenue (TTM)

93.7K

Rev. Growth (Yr)

-96.11%

Rev. Growth (Qtr)

4.14%

AIMD Earnings

Earnings (TTM)

-14.6M

Earnings Growth (Yr)

-31.52%

Earnings Growth (Qtr)

44.05%

Breaking Down AIMD Revenue

52 Week Range

1.06

(Low)(High)

Last 7 days

-2.8%

Last 30 days

2.0%

Last 90 days

25.3%

How does AIMD drawdown profile look like?

AIMD Financial Health

Current Ratio

0.32

AIMD Investor Care

Buy Backs (1Y)

68.64%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.7K	0	0	0
2023	2.7M	1.8M	971.5K	122.1K
2022	679.6K	1.1M	2.5M	3.5M
2021	161.1K	305.6K	450.1K	594.6K
2020	22.9K	22.7K	18.1K	16.6K
2019	25.2K	25.6K	15.4K	11.7K
2018	307.5K	57.3K	72.2K	77.7K
2017	0	195.9K	223.4K	250.9K
2016	113.4K	140.9K	168.4K	0
2015	0	0	0	85.9K
2011	18.5K	31.8K	45.1K	58.4K
2010	0	0	0	5.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ainos, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	sung meng lin	acquired	912	0.8693	1,050	chief financial officer
Feb 16, 2024	lin lawrence k	acquired	312	0.8693	360	e.v.p. of operations
Feb 16, 2024	tsai chun-hsien	acquired	22,688	0.8693	26,100	ceo, president, chairman
Feb 16, 2024	tsai chung-jung	acquired	14,082	0.8693	16,200	-
Feb 16, 2024	lee ting-chuan	acquired	12,517	0.8693	14,400	-
Jan 31, 2024	wei pao-sheng	acquired	1,378	0.94	1,466	-
Jan 31, 2024	tsai chung-yi	acquired	1,378	0.94	1,466	-
Jan 31, 2024	chiang yao-chung	acquired	1,378	0.94	1,466	-
Jan 31, 2024	chang wen-han	acquired	1,378	0.94	1,466	-
Nov 24, 2023	lin lawrence k	acquired	6,000	0.6	10,000	e.v.p. of operations

Which funds bought or sold AIMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-1,050	-	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-22,750	28,500	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	355	5,843	9,650	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	29,168	29,168	-%
May 15, 2024	Hudson Bay Capital Management LP	sold off	-100	-6,323	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	2.8	-6,602	2,992	-%
May 14, 2024	Anson Funds Management LP	sold off	-100	-20,500	-	-%
May 13, 2024	CLEAR STREET LLC	new	-	-	-	-%
May 13, 2024	UBS Group AG	new	-	5.00	5.00	-%
May 13, 2024	UBS Group AG	new	-	13,089	13,089	-%

Are Funds Buying or Selling AIMD?

Are funds buying AIMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AIMD

No. of Funds

Unveiling Ainos, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	ase technology holding co., ltd.	27.4%	2,312,077	SC 13D
Jan 29, 2024	ainos inc	62.05%	2,938,487	SC 13D/A

Recent SEC filings of Ainos, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 08, 2024	3	Insider Trading
May 08, 2024	SC 13D	13D - Major Acquisition
May 06, 2024	8-K	Current Report
May 06, 2024	SC 13D/A	13D - Major Acquisition
Apr 16, 2024	EFFECT	EFFECT
Apr 12, 2024	CORRESP	CORRESP
Apr 11, 2024	UPLOAD	UPLOAD
Apr 08, 2024	S-1	Initial Public Offering

Peers (Alternatives to Ainos, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

Ainos, Inc. News

Latest updates

Ainos, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.1%	20,729	19,904	24,489	28,555	533,290	1,038,026	1,757,774	636,627	87,200	26,399	363,052	202,992	101,840	687	192	484	15,200	2,263	4,786	606	4,076
Cost Of Revenue	-79.6%	26,754	131,307	87,873	55,817	100,848	578,211	1,176,032	318,963	41,078	9,786	103,638	69,508	1,249	56.00	123	292	10,806	2,123	3,368	563	2,718
Gross Profit	94.6%	-6,025	-111,403	-63,384	-27,262	-51,684	459,815	581,742	317,664	46,122	16,613	259,414	133,484	872	631	69.00	192	4,394	140	1,418	43.00	1,358
Operating Expenses	-44.3%	3,114,066	5,589,697	2,612,282	2,289,336	2,461,348	2,586,399	8,404,013	2,261,960	2,129,184	2,312,071	1,442,756	-860,030	522,981	823,707	321,153	300,861	-380,268	369,575	366,824	455,082	391,862
S&GA Expenses	-69.3%	1,029,418	3,352,644	902,017	618,149	762,465	787,531	6,569,227	627,104	551,730	178,194	795,958	860,030	522,981	823,707	321,153	300,472	-380,268	369,575	366,824	404,958	389,476
R&D Expenses	-6.8%	2,084,648	2,237,053	1,710,265	1,671,187	1,698,883	1,798,868	1,834,786	1,634,856	1,577,454	1,273,847	646,798	-	-	-	-	389	-	-	-	50,124	2,386
EBITDA Margin	-41.6%	-102	-72.07	-6.25	-6.02	-3.96	-2.30	-1.24	0.99	3.39	3.88	0.05	0.09	0.16	0.86	-	-	-	-	-	-	-
Interest Expenses	-3.3%	48,696	50,341	44,267	-6,151	9,273	15,914	9,821	3,417	16,687	9,326	-1,711	3,417	11,897	5,290	3,096	1,297	-	176	524	134	69.00
Income Taxes	-100.0%	-	800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	44.0%	-3,314,810	-5,923,701	-2,975,846	-2,349,727	-2,520,475	-3,172,538	-7,821,756	-1,954,032	-16,833	2,161,600	-1,160,110	-749,774	-11,897	-	-323,285	-301,966	-	-	-	-	-
EBT Margin	-37.9%	-155	-112	-11.34	-8.71	-5.79	-3.68	-3.04	-0.87	0.35	0.40	-0.02	-0.03	-0.06	-0.62	-	-	-	-	-	-	-
Net Income	44.0%	-3,314,810	-5,924,501	-2,975,846	-2,349,727	-2,520,475	-2,131,007	-7,821,756	-1,954,032	-2,099,895	-1,444,770	-1,160,110	-749,774	-534,006	-448,493	-323,285	-301,966	-376,879	-370,147	-366,215	-453,517	-391,389
Net Income Margin	-37.9%	-155	-112	-10.27	-8.14	-5.40	-3.98	-5.31	-5.98	-8.03	-6.54	-6.43	-6.73	-9.98	-87.58	-	-	-	-	-	-	-
Free Cashflow	-10.4%	-1,499,175	-1,358,031	-815,485	-1,223,210	-1,499,611	-584,131	-927,258	-375,288	-1,525,788	-783,038	19,432,195	168,811	-211,737	-254,584	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.6%	29,754	31,842	33,860	34,046	36,708	37,109	39,082	40,413	40,736	40,822	19,994	20,622	13,849	7,075	301	337	479	597	692	945	1,226
Current Assets	-39.0%	1,509	2,473	3,040	2,140	3,633	2,846	3,668	3,699	3,023	2,218	885	869	42.00	76.00	158	192	332	445	552	798	1,071
Cash Equivalents	-45.3%	1,031	1,886	2,371	1,361	1,146	1,853	2,417	1,754	1,871	1,751	707	607	9.00	22.00	84.00	173	290	409	483	723	1,046
Inventory	1.2%	170	168	217	528	572	595	-	-	-	-	-	-	-	3.00	3.00	4.00	4.00	4.00	6.00	10.00	9.00
Net PPE	-12.3%	769	877	1,161	1,269	1,315	1,376	1,351	1,503	1,420	1,188	40.00	23.00	3.00	3.00	4.00	4.00	4.00	5.00	2.00	6.00	11.00
Liabilities	-4.3%	7,076	7,394	6,179	3,651	4,370	2,481	2,656	34,407	32,654	30,625	2,857	2,417	1,500	1,099	1,078	881	913	753	613	705	674
Current Liabilities	252.0%	4,706	1,337	819	1,114	1,867	2,473	2,643	6,988	5,730	30,595	2,822	2,376	1,500	1,099	1,078	881	913	753	613	705	674
Shareholder's Equity	-7.2%	22,679	24,448	27,681	30,395	32,338	34,628	36,426	6,006	8,083	10,197	17,136	18,206	-	-	-	-	-	-	79.00	240	552
Retained Earnings	-8.7%	-41,200	-37,886	-31,961	-28,985	-26,636	-24,115	-21,984	-14,162	-12,208	-10,108	-8,664	-7,504	-6,754	-6,220	-5,771	-5,448	-5,146	-4,769	-4,399	-4,033	-3,579
Additional Paid-In Capital	2.6%	64,154	62,556	59,764	59,424	-58,965	58,905	58,492	18,943	20,247	20,204	24,369	24,287	5,055	4,961	4,586	4,495	4,308	4,208	4,076	3,876	3,736
Shares Outstanding	31.4%	6,145	4,678	20,293	20,012	20,012	4,002	19,478	9,625	9,625	9,625	9,496	9,485	2,804	2,804	-	-	-	-	-	-	-
Float	-	-	-	-	5,220	-	3,143	-	-	-	18,258	-	-	-	3,792	-	-	-	9,139	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-8.9%	-1,494	-1,372	-743	-1,151	-1,427	-620	-791	-239	-1,389	-680	-526	169	-211	-254	-	-129	-115	-130	-240	-322	-216
Share Based Compensation	-1.4%	426	432	325	137	221	259	6,076	43.00	43.00	-218	19.00	94.00	94.00	-	-	-	-	-	-	-	-
Cashflow From Investing	-795.4%	-111	16.00	-46.27	1.00	-72.48	35.00	-240	-288	-135	-137	-20.06	-23.28	-	-5.35	-621*	-	-	-11.06	-406*	1*	-1.64
Cashflow From Financing	-13.6%	778	900	1,838	1,391	795	-	1,651	555	1,645	1,864	640	452	199	35.00	75.00	-92.84	103	67.00	-	-	-12.50

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AIMD Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 20,729	$ 49,164
Cost of revenues (including amounts of related party of nil and $46,762 for the three months ended March 31, 2024 and 2023, respectively)	(26,754)	(100,848)
Gross loss	(6,025)	(51,684)
Operating expenses:
Research and development expenses (including amounts of related party of $375,193 and $77,463 for the three months ended March 31, 2024 and 2023, respectively)	2,084,648	1,698,883
Selling, general and administrative expenses	1,029,418	762,465
Total operating expenses	3,114,066	2,461,348
Loss from operations	(3,120,091)	(2,513,032)
Non-operating (expenses) income, net:
Interest expense	(48,696)	(9,273)
Issuance cost of senior secured convertible note measured at fair value	(138,992)
Fair value change for senior secured convertible note	(31,568)
Other income, net	24,537	1,830
Total non-operating expenses, net	(194,719)	(7,443)
Net loss before income taxes	(3,314,810)	(2,520,475)
Provision for income taxes
Net loss	$ (3,314,810)	$ (2,520,475)
Net loss per common share - basic	$ (0.57)	$ (0.63)
Net loss per common share - diluted	$ (0.57)	$ (0.63)
Weighted-average shares used in computing net loss per common share-basic	5,771,283	4,002,210
Weighted-average shares used in computing net loss per common share-diluted	5,771,283	4,002,210

AIMD Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,030,899	$ 1,885,628
Accounts receivable	4,172	455
Inventory, net	169,655	167,593
Other current assets	304,608	419,521
Total current assets	1,509,334	2,473,197
Intangible assets, net	27,155,594	28,283,208
Property and equipment, net	768,665	876,572
Other assets	320,867	208,827
Total assets	29,754,460	31,841,804
Current liabilities:
Contract liabilities	108,000	112,555
Convertible notes payable	3,000,000
Other notes payable, related party	312,000	42,000
Accrued expenses and others current liabilities	1,285,973	1,182,283
Total current liabilities	4,705,973	1,336,838
Senior secured convertible notes measured at fair value	2,369,694	2,651,556
Convertible notes payable		3,000,000
Other notes payable, related party - noncurrent		270,000
Other long-term liabilities		135,829
Total liabilities	7,075,667	7,394,223
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 50,000,000 shares authorized; none issued and outstanding
Common stock, $0.01 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, 6,144,506 and 4,677,787 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	61,445	46,778
Common stock to be issued, 270 shares and 162,337 shares as of March 31, 2024 and December 31, 2023, respectively	3	1,623
Additional paid-in capital	64,154,052	62,555,808
Accumulated deficit	(41,200,965)	(37,886,155)
Accumulated other comprehensive loss - translation adjustment	(335,742)	(270,473)
Total stockholders’ equity	22,678,793	24,447,581
Total liabilities and stockholders’ equity	$ 29,754,460	$ 31,841,804

About Ainos, Inc.

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

CEO	Mr. Chun-Hsien Tsai
WEBSITE	ainos.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	43

Ainos, Inc. Frequently Asked Questions

What is the ticker symbol for Ainos, Inc.? What does AIMD stand for in stocks?

AIMD is the stock ticker symbol of Ainos, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ainos, Inc. (AIMD)?

As of Thu May 16 2024, market cap of Ainos, Inc. is 6.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIMD stock?

You can check AIMD's fair value in chart for subscribers.

What is the fair value of AIMD stock?

You can check AIMD's fair value in chart for subscribers. The fair value of Ainos, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ainos, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AIMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ainos, Inc. a good stock to buy?

The fair value guage provides a quick view whether AIMD is over valued or under valued. Whether Ainos, Inc. is cheap or expensive depends on the assumptions which impact Ainos, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIMD.

What is Ainos, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, AIMD's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 69.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIMD PE ratio will change depending on the future growth rate expectations of investors.